Eichhorst, Barbara (2022). Ibrutinib frontline in young patients with CLL. Blood, 140 (2). S. 80 - 82. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Full text not available from this repository.

Abstract

In this issue of Blood, Shanafelt et al(1) confirm the continued superiority of ibrutinib plus rituximab (IR), compared with the prior standard treatment, fludarabine, cyclophosphamide, and rituximab (FCR), for fit patients with chronic lymphocytic leukemia (CLL). In addition, they report relevant data on the tolerability of continuous treatment with BTK inhibitor.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Eichhorst, BarbaraUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-656953
DOI: 10.1182/blood.2022016535
Journal or Publication Title: Blood
Volume: 140
Number: 2
Page Range: S. 80 - 82
Date: 2022
Publisher: AMER SOC HEMATOLOGY
Place of Publication: WASHINGTON
ISSN: 1528-0020
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
CHRONIC LYMPHOCYTIC-LEUKEMIA; RITUXIMAB; CHEMOIMMUNOTHERAPY; CYCLOPHOSPHAMIDE; FLUDARABINEMultiple languages
HematologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/65695

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item